Trials / Unknown
UnknownNCT01709994
Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients
Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 97 (estimated)
- Sponsor
- Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales · Academic / Other
- Sex
- All
- Age
- 45 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).
Detailed description
Hypothesis: The low-dose aspirin reduces cardiovascular risk in patients with chronic kidney disease without increasing the risk of bleeding
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin | 100 mg/day of aspirin |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2012-10-18
- Last updated
- 2012-10-18
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01709994. Inclusion in this directory is not an endorsement.